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osting by EAbstract In this paper, we described the pharmacological and toxicological studies of three pyraz-
olone derivatives namely PYZ1: 4-[4-N dimethylamino benzylidine]-3-methyl pyrazolin-5(4H)-one,
PYZ2: 4-[2-chlorobenzylidine]-3-methylpyrazolin-5(4H)-one and PYZ3: 4-[benzylidine]-3-meth-
ylpyrazolin-5(4H)-one derivatives. Analgesic, anti-inﬂammatory and antipyretic studies of 3-methyl
pyrazolone derivatives at 400 mg/kg, p.o. have shown signiﬁcant activity as compared to control.
Amongst three pyrazolone derivatives, PYZ2 was found to be more active. Based on the result
of pharmacological studies, PYZ2 was selected for toxicological studies. Acute toxicity studies
revealed that methyl pyrazolone derivatives are non-toxic in rats up to 5000 mg/kg, p.o. The sub-
acute toxicity study of PYZ2 showed that decrease in Hb content, RBC and WBC count. In bio-
chemical analysis level of blood glucose and bilirubin reduced where as AST, ALT and alkaline
phosphatase level elevated. Histopathological studies revealed that there was mild toxicity on liver
and kidney at 1000 mg/kg, p.o.
ª 2011 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.91 9474530205; fax: +91
o.co.in (G. Mariappan).
y. Production and hosting by
Saud University.
lsevier1. Introduction
Pyrazolone ring system represents an important class of com-
pounds not only for their theoretical interest but also for their
anti-inﬂammatory, analgesic, antipyretic (Badaweya et al.,
1998), hypoglycemic agent (Das et al., 2008), fungicide (Singh
and Singh, 1991), antimicrobial (Sahu et al., 2007) and some of
them have been tested as potential cardiovascular drugs
(Yukihito et al., 2006). In the recent year, research is focused
on existing molecules and their modiﬁcations in order to re-
duce their side effects and to explore their other pharmacolog-
ical and biological effects. The most frequently reported side
effects of the pyrazolone derivatives are skin rashes, agranulo-
cytosis, blood dyscrasias which is mostly associated with
116 G. Mariappan et al.aminopyrine, have received wide attention in the medical liter-
ature, but their true incidence with dipyrone is considerably
lower than the often quoted incidence for aminopyrine re-
ported more than 30 years ago (Brogden, 1986). Pyrazolones
are an active moiety in the class of NSAIDs and used in the
treatment of arthritis, musculoskeletal and joint disorder.
Compounds like 3-alkyl-4-aryl methyl pyrazol-5-ones are
reported to exhibit potent antihyperglycemic activity, while
1-phenyl-3-tetraﬂuoroethylpyrazol-5-one is an anxiolytic.
Thus, the biological activities of pyrazol-5-ones depend on
the nature of the substituents (Sil et al., 2005). Edaravone,
3-methyl-1-phenyl-2-pyrazolin-5-one a strong novel free radi-
cal scavenger is used for the treatment of patients with acute
brain infarction (Yukihito et al., 2006). Demethylated antipy-
rine is a novel potent free radical scavenger that has been clin-
ically used to reduce the neuronal damage following ischemic
stroke. Since few literatures reveal the pharmacological and
toxicological studies of pyrazolones, an attempt has been made
to explore the pharmacological properties of novel pyrazolone
derivatives with their toxic effects.2. Materials and methods
2.1. Source of compounds
Pyrazolone derivatives PYZ1, PYZ2 and PYZ3 (Fig. 1) inves-
tigated in the present study were synthesized, characterized in
Department of Pharmaceutical Chemistry, Himalayan Phar-
macy Institute, Sikkim, India (Mariappan et al., 2010).
2.2. Chemicals and drugs
Carboxy methyl cellulose (CMC), acetic acid, eosin, hematox-
ylin, dextrene polystyrene xylene, parafﬁn and xylene were
purchased from S.D. Fine, Mumbai, India. Carrageenan, Fre-
und’s adjuvant and Brewer’s yeast were procured from Sigma,
USA. Indomethacin, paracetamol and aspirin were obtained
from Cipla Pharmaceuticals, Sikkim, India and pentazocine
from Ind-Swift L., Baddi, India as gift sample.
2.3. Biochemical diagnostic kits
Cholesterol, direct HDL-cholesterol, triglycerides, glucose,
AST (GOT), ALT (GPT) and alkaline phosphatase kits were
purchased from Span Diagnostics Ltd., Surat, India.
2.4. Animals
Male and female albino mice (Swiss, 20–25 g), rats (Sprague–
Dawley, 100–150 g) and rabbits (New Zealand strain,N
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H
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Figure 1 Structure and no1.5–2 kg) were used as experimental animals. The animals were
housed under standard conditions of temperature (24 ± 1 C),
relative humidity (65 ± 10%) and 12 h light/dark cycle envi-
ronment. During the study period, guidelines of Committee
for the Purpose of Control and Supervision of Experiments
on Animals (CPCSEA), Institutional Animals Ethics Commit-
tee (IAEC) were followed for the maintenance of animals and
the experimental protocol was approved by Institutional Ani-
mal Ethics Committee (IAEC) No.: HPI/09/60/IAEC/0075.
2.5. Experimental procedure
The animals were divided into ﬁve groups of six in each. The
ﬁrst group was treated as control and received 1% CMC, sec-
ond group received the standard drug (indomethacin 10 mg/
kg, p.o., pentazocine 3.9 mg/kg, i.p., paracetamol 100 mg/kg,
p.o. and aspirin100 mg/kg, p.o.) and rest of the groups were
administered test compounds at 400 mg/kg, p.o.
2.5.1. Analgesic activity
The analgesic activity was evaluated by tail ﬂick and writhing
methods using albino mice adopting standard procedure and
results are reported in Table 1. Overnight fasted healthy and
adult male albino Swiss mice weighing between 20 and 25 g,
in group of six each were taken for the investigation.
2.5.1.1. Tail-ﬂick in mice. Tail ﬂick method (D’Armour and
Smith, 1941) was used to evaluate the analgesic effect of the
pyrazolone compounds. In this method heat is used as a source
of pain. The tips of the animals were individually placed on the
radiant heat source at constant temperature 55 C. The tail
ﬂick response was measured at 0, 1, 2 and 3 h after treatment
of test compounds by digital analgesiometer (INCO, Ambala,
India). The cut-off reaction time was ﬁxed at 10 s to avoid tis-
sue damage. The drug pentazocine (3.9 mg/kg, i.p.) was used
as standard drug for comparison.
2.5.1.2. Acetic acid-induced writhing test. Acetic acid-induced
writhing test was done according to Koster et al. (1959). After
30 min of the administration of the test compounds, all the test
group of mice were administered intra-peritoneally the writh-
ing agent, 1% (v/v) aqueous acetic acid, in a dose of 1 ml/
100 g b.w. The standard group was administered with indo-
methacin (10 mg/kg, p.o.). The numbers of writhing episode
were counted for 30 min and the number of wriths produced
in pyrazolone treated groups was compared with control.
2.5.2. Anti-inﬂammatory activity
2.5.2.1. Carrageenan-induced rat paw edema. The anti-inﬂam-
matory activity of the test compounds was evaluated by
carrageenan-induced rat paw edema model described by Win-O
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Table 1 Analgesic activity of pyrazolone derivatives.
Compound (mg/kg) Tail ﬂick method Writhing test
Average tail withdrawal time (s) No. of writhings
0 h 1 h 2 h 3 h
Control 1.66 ± 0.25 1.66 ± 0.21 1.66 ± 0.21 1.66 ± 0.21 41.7 ± 0.7
Standard (a and b) 1.5 ± 0.30 3.83 ± 0.30** 4.66 ± 0.33** 8.91 ± 0.56** 17.5 ± 0.4**
PYZ1 (400) 1.35 ± 0.21 2.0 ± 0.25 4.16 ± 0.47** 7.16 ± 0.60** 24.5 ± 0.5**
PYZ2 (400) 1.32 ± 0.21 3.16 ± 0.30* 6.33 ± 0.49** 8.5 ± 0.56** 19.4 ± 0.89**
PYZ3 (400) 1.4 ± 0.21 2.0 ± 0.25 4.83 ± 0.60 7.66 ± 0.55 25.4 ± 1.1**
Values are expressed as mean ± SEM (N= 6).
a – Pentazocine (3.9 mg/kg, i.p.) used as standard drug in tail ﬂick method; b – indomethacin (10 mg/kg, p.o.) used as standard drug in writhing
test.
* P< 0.05 compared with vehicle control (ANOVA followed by Dunnett’s test).
** P< 0.01 compared with vehicle control (ANOVA followed by Dunnett’s test).
Table 2 Anti-inﬂammatory activity of pyrazolone derivatives.
Compound
(mg/kg)
Carrageenan-induced paw edema method Freund’s adjuvant method
Paw edema volume in ml (% inhibition of paw edema)
0 h 1 h 2 h 3 h 4 h 0 h 18 h
Control 0.83 ± 0.02 0.90 ± 0.03 1.16 ± 0.09 1.24 ± 0.0 0.98 ± 0.03 0.57 ± 0.02 1.17 ± 0.02
Standard
(a and b)
0.82 ± 0.03 0.94 ± 0.06 0.86 ± 0.02*
(25.86%)
0.70 ± 0.01**
(43.54%)
0.45 ± 0.09**
(54.08%)
0.51 ± 0.01 0.59 ± 0.02**
(49.57%)
PYZ1 (400) 0.80 ± 0.02 0.93 ± 0.04 0.99 ± 0.05
(14.66%)
0.85 ± 0.03**
(31.45%)
0.57 ± 0.01**
(41.83%)
0. 61 ± 0.3 0.71 ± 0.01**
(39.31%)
PYZ2 (400) 0.80 ± 0.02 0.87 ± 0.02 1.05 ± 0.09
(9.48%)
0.72 ± 0.01**
(41.93%)
0.48 ± 0.01**
(51.02%)
0.56 ± 0.2 0.62 ± 0.01**
(47.41%)
PYZ3 (400) 0.81 ± 0.03 0.87 ± 0.02 0.94 ± 0.04
(18.96%)
0.77 ± 0.02**
(37.90%)
0.52 ± 0.01**
(46.93%)
0.58 ± 0.02 0.68 ± 0.01**
(41.37%)
Values are expressed as mean ± SEM (N= 6).
a – Idomethacin (10 mg/kg, p.o.) was used as standard drug in carrageenan-induced paw edema method; b – aspirin (100 mg/kg, p.o.) was used
as standard drug in Freund’s adjuvant method.
* P< 0.05 compared with vehicle control (ANOVA followed by Dunnett’s test).
** P< 0.01 compared with vehicle control (ANOVA followed by Dunnett’s test).
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azolone derivatives (400 mg/kg b.w.) and standard drug indo-
methacin (10 mg/kg b.w.), 1 h prior to the 1% (w/v) solution
injection of 0.1 ml carrageenan into plantar region of right
hind paw (subcutaneously). Paw volume was measured by Ple-
thysmometer (Model 520, IITC, Life Sciences, USA) at 0, 1, 2
and 3 h after carrageenan injection. The difference between the
paw volume at 4th and 0 h measurement was calculated and
taken as edema volume. Percentage inhibition in the paw
was calculated by using the formula, percentage inhibi-
tion = 100 · (1  Vt/Vc), where Vt = mean increase in paw
volume of test, and Vc = mean increase in paw volume of con-
trol. Percentage inhibition shown by tested compounds is re-
corded in Table 2.
2.5.2.2. Freund’s adjuvant-induced polyarthritis model (New-
bould, 1963). The arthritic syndrome was induced in rats by an
injection of 0.1 ml of Freund’s complete adjuvant into the sub-
plantar region of the right hind paw. Animals were treated or-
ally with the pyrazolone derivatives (400 mg/kg) and standarddrug aspirin (100 mg/kg) once daily for 30 days. Plethysmo-
graphic determination of paw volume was performed on in-
jected foot. Paw volume after 18 h was taken as subacute
phase of inﬂammation and that of 30th day was observed as
an index of chronic inﬂammation.
2.5.3. Antipyretic activity
This activity was performed on rabbits of either sex according
to the reported method described by Lu et al. (2004). An ali-
quot of 3 ml/kg of 10% Brewer’s yeast suspension was subcu-
taneously injected into the rabbit back. Temperature was
monitored by means of thermometer inserted at least 10 cm
into the rectum and recorded by calibrated thermometers.
An animal was excluded from the study if the baseline temper-
ature was not within the range of 39.2–39.8 C. After 5 h, ani-
mals showing at least an increase of 1 C of rectal temperature
were selected for the experiment. The animals were adminis-
tered with standard paracetamol (100 mg/kg, p.o.) and pyraz-
olone derivatives (400 mg/kg) orally. The rectal temperature
was measured at 0, 1, 2 and 3 h after treatment.
118 G. Mariappan et al.2.5.4. Acute toxicity study
The Up and Down Procedure (Dixon, 1999) was adopted to
evaluate the acute toxicity of pyrazolone derivatives after oral
administration in rats. Five adult, female, non-pregnant rats
were randomly selected for this experiment. The animals were
marked and housed individually in cages. They were fasted
overnight but allowed free access to water before the adminis-
tration of test compound. Dosing was initiated with 175 mg/kg
and further doses were increased by a factor of 3.2. Pyrazolone
derivatives were administered orally in the form of suspension
with 1% CMC and observed for 48 h for signs of acute toxicity
such as increased–decreased motor activity, ataxia, tremors,
convulsions, sedation and lacrimation, or any instant death.
2.5.5. Subacute toxicity study (Ghosh, 1970; Dixon, 1999;
Derelanko and Hollinger, 2002)
Since PYZ2 had shown promising pharmacological activities,
it was chosen for subacute toxicity study. It was administered
orally to rats for 28 days at the dose of 500 and 1000 mg/kg.
All animals were supplied with standard diet and water during
the testing periods. At the end of the study period on 29th day
the animals were anaesthetized with chloroform and blood
samples immediately collected by cardiac puncture for hema-
tological and biochemical analysis. Necropsy of all the animals
was carried out and selected organs like the heart, liver and
kidney were removed and preserved. The organs were physi-
cally examined, weighed and samples were collected for histo-
pathological examinations.
2.5.5.1. Biochemical assay. The non-heparinized blood was al-
lowed to coagulate before being centrifuged (4000 rpm for
20 min) and the serum separated. The levels of cholesterol
(Chol.), glucose (Glu.) triglycerides (TG), high density lipopro-
tein cholesterol (HDLC), total bilirubin (TB), aspartate trans-
aminase (AST), alanine transaminase (ALT) and alkaline
phosphatase (ALP) were estimated using commercially avail-
able standard kits (Erba Diagnostic Kit and Span Diagnostics
Ltd., India) on an automatic analyzer (Merck P. Ltd.).
2.5.5.2. Hematological assay. At the end of the experimental
period, the next day after an overnight fasting, blood was col-
lected directly from heart and used for the analysis of hemato-
logical parameters viz. Hemoglobin concentration, erythrocyte
count, total and differential leukocyte count, platelet count,
hematocrit and blood clotting time.
2.5.5.2.1. Hemoglobin estimation. Heparinized blood was
taken in the Sahli Hemoglobinometer and diluted with the
0.1 N HCl until the colour matched with the standard. The
reading was taken from graduated cylinder and expressed as
g/dl of blood (Wintrobe et al., 1976; Armour et al., 1965).
2.5.5.2.2. RBC count. The blood sample was diluted 1:100
with the RBC diluting ﬂuid using Thoma pipette after vigorous
mixing, a drop of resultant mixture was discharged under cov-
er glass of Neubauer haemocytometer and corpuscles were al-
lowed to settle for 3 min. The number of RBC in 80 small
squares was counted under light microscope (Wintrobe et al.,
1976; Armour et al., 1965).
2.5.5.2.3. WBC count. The blood sample was diluted 1:20
with the WBC diluting ﬂuid using Thoma pipette after vigor-
ous mixing a drop of resultant mixture was discharged under
cover glass of Neubauer hemocytometer and corpuscles wereallowed to settle for 3 min. The number of WBC in 16 small
squares was counted under light microscope (Wintrobe et al.,
1976; Armour et al., 1965).
2.5.5.2.4. Differential leukocyte count, platelet count and
hematocrit. The heparinized blood was analyzed by digital
automatic hematology analyzer/blood cell counter (Care Well
Biotech Pvt. Ltd., India) in Ashok Laboratories, Jodhpur
Park, Kolkata-32, India and the results were obtained.
2.5.5.2.5. Blood clotting time. The blood sample was taken
with the help of a glass capillary from orbital plexus of the
eye of each rat and the time was noted. Small pieces of capil-
lary were broken from one end at every 30 s till ﬁbrin threads
of blood appeared between the broken ends of capillary (Ghai,
1990).
2.5.5.3. Histopathology. Liver, heart and kidney of animals
from control and treated groups were dissected into small sec-
tions and preserved in cedar wood oil. Inﬁltration was done by
dipping the tissues in xylene:parafﬁn wax in 1:1 ratio for 1 h at
60 C and then tissues were dipped in molten parafﬁn for 1 h at
60 C. The processed tissues were embedded in the molten wax
for section cutting. Thin section of the parafﬁn blocks contain-
ing tissue was done using rotary microtome. Then the slides
were stained with eosin and hematoxylin and mounted with
dextrene polystyrene xylene and examined microscopically
for pathological examination.
2.6. Statistical analysis
All the results were expressed as mean ± SEM. The results
were analyzed by one way analysis of variance (ANOVA) fol-
lowed by Dunnett’s test through the computer program Graph
Pad Instat 3. P value <0.01and <0.05 were considered statis-
tically signiﬁcant.3. Results
Table 1 shows the analgesic activity by tail ﬂick and acetic
acid-induced writhing methods using pentazocine and indo-
methacin as standard drugs, respectively. All the compounds
showed signiﬁcant analgesic activities in both methods.
PYZ2 has shown more prominent analgesic response at
400 mg/kg b.w. since it was found to be more effective at the
end of 4 h similar to the standard drug indomethacin (10 mg/
kg, p.o.). Anti-inﬂammatory activity was screened by carra-
geenan-induced acute inﬂammation model and adjuvant-in-
duced arthritis model and results are presented in Table 2.
The results of carrageenan induced model revealed that
PYZ2 was more active at 4 h (51.02% inhibition) of paw ede-
ma which is comparable to the standard indomethacin
(54.08% inhibition). The results of adjuvant-induced arthritis
model showed that PYZ2 (47.41% inhibition), activity was
comparable to standard drug aspirin (49.57% inhibition) after
30 days administration. The perusal of results of antipyretic
study revealed that signiﬁcantly all the compounds reversed
hyperthermia similar to standard drug paracetamol (100 mg/
kg, p.o.) as shown in Table 3. Amongst them, PYZ2 was found
to be more active (37.8 C) which is similar to standard para-
cetamol (37.46 C). Acute toxicity and gross behavior studies
revealed that the test compounds in the present investigation
Table 3 Effect of pyrazolone derivatives on yeast induced pyrexia in rabbits.
Treatment (mg/kg, p.o.) Rectal temperature (C)
Time (h)
0 1 2 3
Control 41.03 ± 0.16 41.08 ± 0.13 40.86 ± 0.21 40.86 ± 0.21
Standard paracetamol (100) 40.96 ± 0.26 40.76 ± 0.28 37.93 ± 0.24** 37.46 ± 0.15**
PYZ1 (400) 40.98 ± 0.12 40.46 ± 0.12 39.76 ± 0.21* 38.76 ± 0.16**
PYZ2 (400) 40.6 ± 0.38 40.48 ± 0.07 38.65 ± 0.37** 37.8 ± 0.16**
PYZ3 (400) 40.85 ± 0.28 40.51 ± 0.21 39.71 ± 0.29* 38.13 ± 0.24**
Values are expressed as mean ± SEM (N= 6).
* P< 0.05 compared with vehicle control (ANOVA followed by Dunnett’s test).
** P< 0.01 compared with vehicle control (ANOVA followed by Dunnett’s test).
Table 4 Hematological parameters of PYZ2 treated rats.
Male Female
Control 500 mg/kg 1000 mg/kg Control 500 mg/kg 1000 mg/kg
RBCa 8.6 ± 0.23 7.9 ± 0.57* 6.5 ± 0.56* 8.35 ± 0.34 7.27 ± 0.64* 6.21 ± 0.78*
Hbb 15.32 ± 0.98 14.83 ± 0.76* 10.34 ± 0.72* 13.9 ± 0.57 12.83 ± 0.78* 9.43 ± 0.38*
Hrc 46.56 ± 2.08 46.65 ± 1.34* 46.23 ± 2.08* 44.34 ± 2.56 43.23 ± 1.9* 43.43 ± 1.3*
WBCd 6.73 ± 2.01 5.28 ± 1.22* 4.65 ± 2.34* 5.15 ± 1.58 4.78 ± 2.48* 4.12 ± 2.08*
Lymp.e 70.41 ± 6.21 69.9 ± 9.16* 68.62 ± 9.78* 84.47 ± 1.65 81.67 ± 4.6* 80.54 ± 3.2*
Mono.f 3.83 ± 0.12 3.2 ± 0.22* 3.6 ± 0.7* 2.9 ± 0.87 2.7 ± 0.55* 2.04 ± 0.28*
Eosi.g 0.7 ± 0.03 0.57 ± 0.07* 0.46 ± 0.02* 0.6 ± 0.02 0.5 ± 0.03* 0.29 ± 0.04*
PLT.h 912.1 ± 98 925.2 ± 102* 968.9 ± 79* 911.6 ± 78.9 947.6 ± 47.9* 928.3 ± 50.7*
ClT.i 2.01 ± 0.5 2.35 ± 0.76* 2.15 ± 0.65* 2.77 ± 0.19 2.49 ± 0.45* 2.65 ± 0.97*
Data are expressed as mean ± SEM (N= 5).
a Red blood cell (·106 mm3).
b Hemoglobin concentration (g/dl).
c Hematocrit (%).
d White blood cell (·103 mm3).
e Lymphocyte (%).
f Monocyte (%).
g Eosinophilic leukocyte (%).
h Platlets (·103 mm3).
i Clotting time (min).
* All the P values are <0.05 as compared to respective controls by Dunnett’s test.
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ical changes have been observed such as depletion of hemoglo-
bin; RBC and WBC count in dose dependent manner of PYZ2
treated rats on either sex. In case of hematocrit, no signiﬁcance
difference was observed between control and treated male
groups at 500 and 1000 mg/kg b.w. But this value was slightly
reduced in female rats as compared to control at 500 and
1000 mg/kg b.w. (Table 4). Differential leukocyte count
(DLC) determination showed eosinopenia at higher dose
(1000 mg/kg b.w.). The level of lymphocyte and monocyte is
slightly reduced as compared to control in dose dependent
manner in PYZ2 treated groups of either sex. The platelets
count is increased in treated rats in dose dependent manner.
The clotting time is altered in PYZ2 treated groups of either
sex and change is within the normal range. Biochemical
parameters showed that decrease of total bilirubin and blood
glucose in both 500 and 1000 mg/kg b.w. dose of PYZ2 treated
groups as compared to control. The elevation of lysosomal en-
zymes such as ALP, AST and ALT level were observed in ani-
mals with treated PYZ2 in dose dependent manner. No
signiﬁcant changes were observed in HDL, cholesterol and tri-glycerides level (Table 5). The histopathological studies re-
vealed that some toxic changes have been observed in PYZ2
treated animals at cellular level. The structural changes like
cytoplasm vacuolation and degranulation of nucleus in hepatic
cells were also observed. Dilated globules and atrophied
glomeruli were seen in kidney. Interestingly no toxic effects
were observed on myocardium in Fig. 2.4. Discussion
The mechanism for testing analgesic was selected such that
both centrally and peripherally mediated effects were investi-
gated. The acetic acid induced abdominal constriction and tail
immersion methods elucidated peripheral and central activity,
respectively. This test is very useful not only for assessing anal-
gesic drugs but also helping in the elucidation of mode of ac-
tion. Acetic acid which is used as an inducer for writhing
syndrome (Koster et al., 1959) causes an algesia by releasing
of endogenous substances, which then excite the pain nerve
ending. The abdominal constriction is related to the sensitiza-
Table 5 Biochemical parameters of PYZ2 treated rats.
Male Female
Control 500 mg/kg 1000 mg/kg Control 500 mg/kg 1000 mg/kg
TBa 0.27 ± 0.005 0.24 ± 0.06* 0.26 ± 0.02* 0.22 ± 0.034 0.20 ± 0.07* 0.21 ± 0.02*
ASTb 173.6 ± 29.5 178.2 ± 21.4 224.6 ± 19.6 167.7 ± 12.5 185.6 ± 19.5 191.47 ± 15.3
ALTc 48.2 ± 3.9 48.4 ± 3.5 65.3 ± 0.69 48.09 ± 0.92 52.2 ± 0.45 57.2 ± 0.89
HDLd 35.1 ± 4.28 36.2 ± 5.1 36.5 ± 4.9 36.89 ± 3.4 36.4 ± 2.4 36.8 ± 2.1
Chol.e 56.3 ± 3.2 55.7 ± 3.7 56.5 ± 4.6 55.8 ± 3.9 56.4 ± 5.9 54.7 ± 4.8
TGf 42.3 ± 14.3 42.5 ± 14.5 43.6 ± 11.8 45.3 ± 10.3 45.2 ± 9.4 44.48 ± 11.2
Glu.g 100.3 ± 0.87 86.7 ± 2.6* 77.07 ± 2.9* 119.2 ± 2.67 106.3 ± 1.7* 92.4 ± 2.65*
ALPh 39.2 ± 0.55 41.4 ± 0.76 43.6 ± 0.89 38.4 ± 0.46 39.2 ± 0.65 43.7 ± 0.83
Data are expressed as mean ± SEM (N= 5).
a Total bilirubin (mg/dl).
b Aspartate transaminase (U/l) S.G.O.T.
c Alanine transaminase (U/l) S.G.P.T.
d High density lipoprotein (mg/dl).
e Cholesterol (mg/dl).
f Triglycerides (mg/dl).
g Glucose (mg/dl).
h Alkaline phosphatase (U/l).
* P< 0.05 compared with vehicle control (ANOVA followed by Dunnett’s test).
(a)                                         (b) 
(c)                                        (d)
(e)                                          (f) 
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Figure 2 Histological changes of liver, kidney and heart from PYZ2 treated rats. (a) Liver from control, (b) PYZ2 liver from treated, (c)
kidney from control, (d) PYZ2 kidney from treated, (e) heart from control and (f) PYZ2 heart from treated rats.
120 G. Mariappan et al.tion of nociceptive receptors to prostaglandins. Prostaglandins
cause pain (Roberts and Morrow, 2001) and sensitize the skin
to painful stimuli (Dray, 1995) probably because they sensitize
pain receptors to mechanical and chemical stimulation(Roberts and Morrow, 2001) such as the pain eliciting effect
of mediators (e.g. histamine, kinins, etc.) which are released
in tissue injury and inﬂammation. The inhibition of the synthe-
sis of pro-inﬂammatory prostaglandins is one of such therapeu-
Analgesic, anti-inﬂammatory, antipyretic and toxicological evaluation of some newer 3-methyl pyrazolone derivatives 121tic targets to which some of the potent analgesic and anti-
inﬂammatory agents of clinical relevance (e.g. NSAIDs) owe
their activity (Flower and Vane, 1974). The pyrazolone deriva-
tives administered orally (400 mg/kg); signiﬁcantly inhibit ace-
tic acid-induced writhing in rats. The result strongly suggests
that the mechanism of action of pyrazolones may be linked
to lipoxygenase and/or cyclooxygenase inhibition. It is possible
that pyrazolone exert an analgesic effect probably by inhibiting
prostaglandin synthesis by blocking cyclooxygenase enzyme.
The inﬂammatory response involves a complex array of en-
zyme activation, mediator release, ﬂuid extravasations, cell
migration, tissue breakdown and repair (Vane and Bolting,
1995) which are aimed at host defense and usually activated
in most disease conditions. These different reactions in the
inﬂammatory response cascade are therapeutic targets which
anti-inﬂammatory agents interfere with to suppress exacer-
bated inﬂammatory responses usually invoked in such disor-
ders such as rheumatoid arthritis, infection or injury.
The non-steroidal anti-inﬂammatory drugs exert anti-
inﬂammatory effect principally by inhibiting the synthesis of
prostaglandin an eicosanoid mediator of the inﬂammatory
response (Foegh and Ramwell, 2001). The most widely used
primary test to screen new anti-inﬂammatory agent’s ability
to reduce local edema induced in the rat paw by injection of
an irritant agent. Carrageenan-induced edema has been com-
monly used as an experimental animal model for acute inﬂam-
mation and is believed to be biphasic. The carrageenan test
was selected because of its sensitivity in defecting orally active
anti-inﬂammatory agents particularly in the acute phase of
inﬂammation (Dirosa et al., 1971). The subplantar injection
of carrageenan in rats leads to paw edema. The early phase
(1–2 h) carrageenan model is mainly mediated by histamine,
serotonin and increased synthesis of prostaglandins in the
damaged tissues surroundings. The late phase is sustained by
prostaglandin release and mediated by bradykinin, leukotri-
enes, polymorph nuclear cells and prostaglandins produced
by tissues macrophages (Brito and Antonio, 1998). The pyraz-
olone derivatives reduced the carrageenan-induced paw edema
in rats. It may be due to inhibition of cyclooxygenase which
activates prostaglandin synthesis followed by prevention of
inﬂammatory mediator’s release.
In Freund’s adjuvant-induced polyarthritis model, treat-
ment with pyrazolone derivatives showed signiﬁcant inhibitory
effect on injected hind paw edema and maximum inhibition
was observed on the 30th day. In the present study, the in-
creased lymphocyte count and migration of leucocytes into
the inﬂamed area of arthritic rats were signiﬁcantly prevented
with the treatment of the pyrazolone derivatives and the stan-
dard drug as reﬂected from the signiﬁcant decrease in total
WBC count (Saraf et al., 1989).
Fever results due to generation of mediators such as IL-1b,
IL-6, interferons and TNF-a cytokines increase the synthesis
of prostaglandin which elevates the body temperature. From
the results of antipyretics study, it can be suggested that pyraz-
olone derivatives produce the antipyretic action by inhibiting
the prostaglandin synthesis by blocking cyclooxygenase isoen-
zymes, platelet thromboxane synthesis, and prostanoids syn-
thesis (Graham and Scott, 2003; Bentur and Cohen, 2004).
Inﬂammatory process is characterized by the involvement
of multiple inﬂammatory cells of the WBC (Kytridis and Man-
etas, 2006). WBC and indices relating to it such as lymphocytes
usually show increase in activity in response to toxic environ-ment (Robins, 1974). In this study, WBC was signiﬁcantly
altered. The lymphocytes, the main effector cells of the
immune system (McKnight et al., 1999) showed marginal
decrease thus suggesting that the pyrazolones only exerted
minimal challenge on the immune system of the animals.
Moreover, the decreased level of lymphocytes and monocytes
clearly proving that pyrazolone derivatives are responsible
for agranulocytosis. Our result is consistent with the result ob-
tained from previous researchers (Bentur and Cohen, 2004;
Uetrecht et al., 1995). Generally pyrazolones are associated
with toxic effects such as thrombocytopenia (Flower, 1983;
Yu, 1974) but in this study PYZ2 elevated the level of platelets
at 500 and 1000 mg/kg b.w. This proves that the structural
modiﬁcation of pyrazolones may reduce the mentioned toxic
effect.
The hematocrit raises when the number of red blood cells
increases or when the plasma volume is reduced, as in
erythrocytosis. It falls to less than normal, indicating anemia
(Hoffman et al., 2005; Mcpherson and Pincus, 2007). In both
male and female rats, the hematocrit value is within the normal
range (male 40–50% and female 36–44%) (Table 4). There is
increasing evidence that lysosomal enzymes (ALT, AST and
ALP) play an important role in the development of acute
and chronic inﬂammation (Jannoff and Zweifach, 1964;
Anderson et al., 1971).
Most of anti-inﬂammatory drugs exert their beneﬁcial effect
by inhibiting either release of lysosomal enzymes or by stabiliz-
ing lysosomal membrane which is one of the major events
responsible for the inﬂammatory process. The stabilization
of lysosomal membranes is important in limiting the inﬂamma-
tory response by preventing the release of lysosomal constitu-
ents of activated neutrophil such as bactericidal enzymes and
proteases, which cause further tissue inﬂammation and dam-
age upon extracellular release (Chou, 1997). Some NSAIDs
like indomethacin and acetylsalicylic acid are known to possess
membrane stabilizing properties (Murugesh et al., 1981; Furst
and Munster, 2001) which may contribute to the potency of
their anti-inﬂammatory effect. In a toxic environment, blood
level of AST and ALT are known to signiﬁcantly increase
(Adam, 1998; Crook, 2006). These two classical enzymes are
reliable indices of liver toxicity. From the subacute toxicity it
can be assumed that the increased level of alkaline phospha-
tase, AST and ALT level may be responsible for the tissues
damages in the liver and kidney. This was conﬁrmed by the
histological study in which tissue morphology showed mild
changes on liver and kidney.
The histopathological studies revealed that PYZ2 has mild
toxicity on liver and kidney with the exception on heart. This
supports that pyrazolones have no toxic effect on heart on 500
and 1000 mg/kg b.w. The present experimental ﬁndings of
both pharmacological and toxicological parameters suggest
that pyrazolone derivatives are the promising non-steroidal
anti-inﬂammatory agents. Hence it can be concluded that it
is worthwhile to modify the structure to obtain more potent
and less toxic compound.Acknowledgement
The authors are very grateful to the Director, Dr. H.P. Chhe-
tri, Himalayan Pharmacy Institute, Sikkim, India for provid-
ing facilities for this research work.
122 G. Mariappan et al.References
Adam, S.E.I., 1998. Toxic effects of Francoeuria crispa in rats.
Phytother. Res. 2, 476–479.
Anderson, A.J., Bocklehurst, W.E., Wills, A.L., 1971. Evidence for the
role of lysosomes in the formation of prostaglandin during
carrageenan-induced inﬂammation in rat. Pharmacol. Res. Com-
mun. 3, 13–17.
Armour, D.F.E., Blood, F.R., Belden, D.A., 1965. In the Manual of
Laboratory Work in Mammalian Physiology, third ed. The
University of Chicago Press, Liilious, Chicago, pp. 4–6.
Badaweya, El-Sayed, A.M., El-Ashmawey, Ibrahim, M., 1998. Non-
steroidal anti-inﬂammatory agents – Part 1: Anti-inﬂammatory,
analgesic and antipyretic activity of some new 1-(pyrimidin-2-yl)-3-
pyrazolin-5-ones and 2-(pyrimidin-2-yl)-1,2,4,5,6,7-hexahydro-3H
indazol-3-ones. J. Med. Chem. 33, 349–361.
Bentur, Y., Cohen, O., 2004. Dipyrone overdose. J. Toxicol. Clin.
Toxicol. 42, 261–265.
Brito, A.R.M.S., Antonio, M.A., 1998. Oral antiinﬂammatory and
antiulcerogenic activities of a hydroalcoholic extract and parti-
tioned fractions of Turnera ulmifolia (Turneraceae). J. Ethnophar-
macol. 61, 215–228.
Brogden, R.N., 1986. Pyrazolone derivatives. Drugs 32 (4), 60–70.
Chou, C.T., 1997. The anti-inﬂammatory effect of Tripterygium
wilfordii on adjuvant-induced paw edema in rats and inﬂammatory
mediators release. Phytother. Res. 11, 152–154.
Crook, M.A., 2006. Clinical Chemistry and Metabolic Medicine,
seventh ed. Hodder Arnold, London, p. 426.
D’Armour, F.E., Smith, D.L., 1941. A method for determining loss of
pain sensation. J. Pharmacol. Exp. Ther. 72, 74–79.
Das, N., Verma, A., Shrivastava, P.K., Shrivastava, S.K., 2008.
Synthesis and biological evaluation of some new aryl pyrazol-3-one
derivatives as potential hypoglycemic agents. Indian J. Chem. 47B,
1555–1558.
Derelanko, M.J., Hollinger, M.A., 2002. Acute, subacute and chronic
toxicology. Hand Book of Toxicology, second ed. CRC Press, New
York, pp. 69–127.
Dirosa, M., Giroud, J.P., Willoughby, D.A., 1971. Studies of the acute
inﬂammatory response induced in rats in different sites by
carrageenan and turpentine. J. Pathol. 104, 15–29.
Dixon, W.J., 1999. Staircase bioassay: the Up and Down method.
Neurosci. Biobehav. Rev. 15, 47–50.
Dray, A., 1995. Inﬂammatory mediators of pain. Br. J. Anaesth. 75,
125–131.
Flower, R.J., 1983. Management of rheumatoid arthritis and osteo-
arthritis. Am. J. Med. 75 (4), 1–91.
Flower, R.J., Vane, J.R., 1974. Inhibition of prostaglandins synthesis.
Biochem. Pharmacol. 23, 1439–1450.
Foegh, M.L., Ramwell, P.W., 2001. The eicosanoids: prostaglandins,
thromboxanes, leukotrienes, and related compounds. In: Kartzung,
B.G. (Ed.), Basic and Clinical Pharmacology, eighth ed. Lange
Medical Books/McGraw-Hill, New York, pp. 311–325.
Furst, D.E., Munster, T., 2001. Nonsteroidal anti-inﬂammatory drugs,
disease-modifying antirheumatic drugs, nonopoid analgesics and
drugs used in gout. In: Kartzung, B.G. (Ed.), Basic and Clinical
Pharmacology, eighth ed. Lange Medical Books/McGraw-Hill,
New York, pp. 596–623.
Ghai, C.L., 1990. Textbook of Practical Physiology. Jaypee Medical
Publishers, New Delhi, pp. 102–104.
Ghosh, M.N., 1970. Fundamentals of Experimental Pharmacology,
fourth ed. Hilton and Company, Kolkata, pp. 176–183.
Graham, G.G., Scott, K.F., 2003. Mechanisms of action of paracet-
amol and related analgesics. Inﬂammopharmacology 11, 401–
413.
Hoffman, R., Benz, E.J., Shattil, S.J., 2005. Hematology: Basic
Principles and Practice, fourth ed. Churchill Livingstone, Philadel-
phia, p. 2674.Jannoff, A., Zweifach, B.W., 1964. Production of inﬂammatory
changes in the micro-circulation by cationic proteins extracted
from lysosomes. J. Exp. Med. 120, 747–764.
Koster, R., Anderson, M., De Beer, E.J., 1959. Acetic acid for
analgesic screening. Fed. Proc. 18, 412–416.
Kytridis, V.P., Manetas, Y., 2006. Mesophyll versus epidermal
anthocyanins as potential in vivo antioxidants: evidence linking
the putative antioxidant role to the proximity of oxy-radical source.
J. Exp. Bot. 57, 2203–2210.
Lu, W.L., Zhang, Q., Zheng, L., Wang, H., Li, R.Y., Zhang, L.F.,
2004. Antipyretic, analgesic and anti-inﬂammatory activities of
ketoprofen beta-cyclodextrin inclusion complexes in animals. Biol.
Pharm. Bull. 27 (10), 1516–1520.
Mariappan, G., Saha, B.P., Sutharson, L., Haldar, A., 2010. Synthesis
and bioactivtiy evaluation of pyrazolone derivatives. Indian
J.Chem. 47B, 1671–1674.
McKnight, D.C., Mills, R.G., Bray, J.J., Crag, P.A., 1999.
Human Physiology, fourth ed. Churchill Livingstone, pp. 290–
294.
Mcpherson, R.A., Pincus, M.R., 2007. Henry’s Clinical Diagnosis and
Management by Laboratory Methods, 21st ed. WB Saunders,
Philadelphia, pp. 459–460.
Murugesh, N., Vember, S., Damondaran, C., 1981. Studies on
erythrocyte membrane IV: in vitro haemolytic activity of oleander
extract. Toxicol. Lett. 8, 33–38.
Newbould, B.B., 1963. Chemotherapy of arthritis induced in rats by
mycobacterial adjuvant. Br. J. Pharmacol. 21, 127–136.
Roberts, J.L., Morrow, J.D., 2001. Analgesic–antipyretic and anti-
inﬂammatory agents and drugs employed in the treatment of gout.
In: Gilman, A.G., Hardman, J.G., Limbird, L.E. (Eds.), Goodman
and Gilman’s The Pharmacological Basis of Therapeutics, 10th ed.
McGraw Hill Co., New York, pp. 687–731.
Robins, S.L., 1974. Lymph Nodes and Spleen: Pathologic Basis of
Disease. WB Saunders Co., Philadelphia, p. 1050.
Sahu, S.K., Azam, A.M., Banerjee, M., Choudhary, P., Sutradhar, S.,
Panda, P.K., Misra, P.K., 2007. Synthesis and biological evalu-
ation of 3-(pthalimidomethyl)-4-(5-substituted isoxazoline and
pyrazoline) substituted benzanilides. J. Indian Chem. Soc. 84,
1011–1015.
Saraf, M.N., Ghooi, R.B., Patavardhan, B.K., 1989. Studies on the
mechanism of action of Semecarpus anacardum in rheumatoid
arthritis. J. Ethnopharmacol. 25, 159–164.
Sil, D., Kumar, R., Sharon, A., Maulik, Prakas, R., Ram, V., 2005.
Stereoselective alkenylation of 1,3-disubstituted pyrazol-5-one
through ring transformation of 2H-pyran-2-ones. Tetrahedron
Lett. 46 (22), 3807–3809.
Singh, D., Singh, D., 1991. Synthesis and antifungal activity of some 4-
arylmetylene derivatives of substituted pyrazolones. J. Indian
Chem. Soc. 68, 165–167.
Uetrecht, J.P., Ma, H.M., MacKnight, E., McClelland, R., 1995.
Oxidation of aminopyrine by hypochlorite to a reactive dication:
possible implications for aminopyrine-induced agranulocytosis.
Chem. Res. Toxicol. 8, 226–233.
Vane, J.R., Bolting, R.M., 1995. New insights into the mode of action
of anti-inﬂammatory drugs. Inﬂamm. Res. 44 (1), 1–10.
Winter, C.A., Risely, E.A., Nuss, G.W., 1962. Carrageenan induced
edema in hind paw of the rat as an assay for anti-inﬂammatory
drug. Proc. Soc. Exp. Biol. Med. 111, 544–547.
Wintrobe, M.M., Lee, G.R., Boggs, D.R., Bithel, T.C., Athens, J.W.,
Foeresters, J., 1976. Clinical Hematology, seventh ed. Les and
Febiger, Philadelphia, p. 961.
Yu, E.T., 1974. Milestone in the treatment of gout. Am. J. Med. 56 (4),
676–683.
Yukihito, H., Daisuke, J., Kazuaki, C., Masao, Y., 2006. Edaravone
(3-methyl-1-phenyl-2-pyrazolin-5-one), a novel free radical scaven-
ger, for treatment of cardiovascular diseases. Recent Patent
Cardiovasc. Drug Discov. 1, 85–93.
